Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SaLuDo: Lurbinectedin + Doxorubicin in Metastatic Leiomyosarcoma
NCT06088290Phase 3Active, not recruiting
- Sponsor
- PharmaMar
- Start
- Sep 2023
- Primary completion
- Aug 2029
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of lurbinectedin in leiomyosarcoma (LMS) (3 arms), sponsored by PharmaMar. Primary endpoint: Progression-Free Survival by Independent Review Committee at 41 months. Started Sep 2023; status: active, not recruiting.
02
Drugs
lurbinectedin
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT06088290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06088290.